Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.43 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 4/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | GPR6 | P46095 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436735 | 0.88 | OPRK1 (0.43) | OPRK1ACACBHRH3SMOMAPT | |
| SCHEMBL3436535 | 0.80 | HRH3 (0.47) | HRH3KMT2A | |
| SCHEMBL3561809 | 0.79 | MAPT (0.58) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL3436736 | 0.76 | OPRK1 (0.41) | OPRK1ACACBSMOGPR6 | |
| SCHEMBL3557685 | 0.76 | KDM4E (0.52) | OPRK1CYP2C19GAAKDM4E | |
| SCHEMBL20135640 | 0.75 | SSTR2 (0.47) | OPRK1SMO | |
| SCHEMBL3436555 | 0.75 | ALDH1A1 (0.53) | OPRK1MAPTKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5252865 | 0.73 | OPRK1 (0.46) | OPRK1ACACBHRH3MAPTCYP2C9 | |
| SCHEMBL22322387 | 0.73 | ACACB (0.38) | OPRK1ACACBHRH3MAPTCYP2C9 | |
| SCHEMBL19049948 | 0.72 | CHRM4 (0.54) | ACACBGPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | OPRK1 237/4885ACACB 3203/4885HRH3 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.